Drugmaker AbbVie said it will buy Pharmacyclics for about $21 billion to boost its oncology drugs pipeline.» Read More
Allergan may be more effective in its defense against a hostile takeover bid by Valeant Pharmaceuticals if it makes a purchase of its own, an analyst says.
The chief executive of AstraZeneca, at the center of speculation of a $101 billion takeover, has said such large-scale deals are "often disruptive."
Novartis posted first-quarter profit that beat expectations, boosted by an exceptional gain from the sale of its blood transfusion test unit.
Drugmakers eager to satisfy shareholders are wheeling, dealing, and in one case even making trades like a pro sports team looking to shake up its roster.
Gilead's net profit nearly tripled and revenue was more than $1 billion ahead of estimates, thanks to sales of a key Hepatitis C drug.
More than half the revenue from Botox comes from therapeutic, not cosmetic, use. And its potential is helping to make Allergan an attractive target.
Male doctors on average make 88 percent more in Medicare reimbursements than female physicians, according to an analysis of government data.
The megabillion-dollar deals with Novartis also allow GlaxoSmithKline to "significantly expand" its world-leading vaccine business, GSK's CEO tells CNBC.
Pharmaceutical industry observers have been waiting for a rush of deals for months - and they might have finally arrived.
JPMorgan Chase's Mike Weinstein gives his top health care picks to buy right now, in light of recent weakness in the sector.
There are some solid reasons why Pfizer's reported $101 billion bid for AstraZeneca makes some sense, analysts said.
Activist investor William Ackman of Pershing Square Capital and Valeant Pharmaceuticals International are said to be pursuing a takeover of Allergan.
Biotech earnings kick off Tuesday after the bell as Gilead and Amgen report. Here's what to watch for.
Sarepta Therapeutics got the go-ahead to file for approval of its experimental drug for Duchenne muscular dystrophy.
HealthCare.gov warned enrollees that their passwords had been reset to guard against the "Heartbleed" bug.
Enrollment in private Obamacare plans topped 8 million, the president announced Thursday.
California enrolled about 3.3 million in either private Obamacare plans or the state's version of Medicaid, officials announced Thursday.
This week the headline appeared to have some tough news for RNA companies, but Alnylam remains undeterred about the potential of its treatments.
According to a Gallup poll, Obamacare helped 10 million Americans to get new health insurance, making the percentage of insured people plummet.
UnitedHealth Group's earnings outlook will be limited, according to Citi analyst Carl McDonald, who downgraded shares of the nation's largest insurer to "neutral" from "buy."
Get the best of CNBC in your inbox